What are the initial pharmacological therapies for treating hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Pharmacological Therapies for Treating Hypertension

The first-line pharmacological agents for treating hypertension include thiazide and thiazide-like diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs). 1, 2

Blood Pressure Thresholds for Initiating Treatment

  • Pharmacological treatment is recommended for individuals with confirmed hypertension and systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg 2
  • For patients with high cardiovascular risk, diabetes mellitus, or chronic kidney disease, treatment should be considered when SBP is 130-139 mmHg 1, 2
  • For patients with known cardiovascular disease, treatment is recommended when SBP is 130-139 mmHg 1, 2

First-Line Medication Selection

  • Any of these four drug classes can be used as initial therapy based on their proven efficacy in reducing cardiovascular events in people with hypertension 1:

    • Thiazide or thiazide-like diuretics (e.g., chlorthalidone, hydrochlorothiazide)
    • ACE inhibitors (e.g., lisinopril)
    • ARBs (e.g., losartan)
    • Long-acting dihydropyridine calcium channel blockers (e.g., amlodipine)
  • Initial medication selection should be guided by patient-specific factors 1, 2:

    • For patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), an ACE inhibitor or ARB is recommended 1, 2
    • For patients with diabetes and established coronary artery disease, ACE inhibitors or ARBs are preferred 1
    • For Black patients, thiazide diuretics or CCBs may be more effective as initial therapy than ACE inhibitors 1, 2

Single vs. Combination Therapy Approach

  • For patients with BP between 130/80 mmHg and 150/90 mmHg, treatment may begin with a single agent 1
  • For patients with BP ≥150/90 mmHg or with BP more than 20/10 mmHg above their target, initial therapy with two antihypertensive medications from different classes is recommended 1
  • Single-pill combinations may improve medication adherence 1

Dosing and Titration

  • For ACE inhibitors like lisinopril, the recommended initial dose is 10 mg once daily, with typical dosage range of 20-40 mg per day 3
  • For ARBs like losartan, the usual starting dose is 50 mg once daily, which can be increased to a maximum of 100 mg once daily as needed 4
  • If blood pressure is not controlled with monotherapy, a low dose of a diuretic may be added (e.g., hydrochlorothiazide 12.5 mg) 3

Target Blood Pressure Goals

  • For patients without comorbidities, the target blood pressure goal is <140/90 mmHg 1, 2
  • For patients with known cardiovascular disease, the target systolic blood pressure goal is <130 mmHg 1, 2
  • For high-risk patients (high cardiovascular risk, diabetes mellitus, or chronic kidney disease), the target systolic blood pressure goal is <130 mmHg 1

Monitoring and Follow-up

  • Monthly follow-up is recommended after initiation or change in antihypertensive medications until target BP is reached 1
  • For patients with controlled BP, follow-up every 3-5 months is suggested 1
  • Monitor serum creatinine and potassium levels when using ACE inhibitors, ARBs, or diuretics 1

Common Pitfalls to Avoid

  • Avoid combinations of ACE inhibitors and ARBs due to increased risk of adverse events without additional benefit 2
  • Do not use immediate-release nifedipine due to risk of rapid blood pressure reduction 5
  • Avoid delaying treatment to complete cardiovascular risk assessment; this can be done after initiation of therapy 2
  • Beta-blockers are not recommended as first-line therapy unless there are specific indications such as prior myocardial infarction, active angina, or heart failure 1

Special Considerations

  • In patients with impaired renal function, dose adjustments may be necessary for ACE inhibitors and ARBs 3, 4
  • ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists should be avoided in sexually active individuals of childbearing potential who are not using reliable contraception 1
  • For resistant hypertension (BP ≥140/90 mmHg despite three antihypertensive medications including a diuretic), consider adding a mineralocorticoid receptor antagonist 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Pharmacological Management for Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hypertensive crisis.

Cardiology in review, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.